Suren R Karagulyan
Research Subjects
Suren R Karagulyan has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Anait Levonovna Melikyan
National Medical Research Center for Hematology
2 shared publications - Eduard G. Gemdzhian
National Medical Research Center for Hematology
2 shared publications Alla M. Kovrigina
National Reserch Center for Hematology, Moscow, Russia
1 shared publication- E. I. Pustovaya
National Research Center for Hematology
1 shared publication Eduard G. Gemdjian
Laboratory of Biostatistics, National Research Center for Hematology, Moscow, Russia
1 shared publication- Elena A. Gilyazitdinova
National Medical Research Center for Hematology
1 shared publication
Latest Publications
- Open Access
- 25 October 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (3) , 362-373-373
Effi cacy of splenectomy in primary immune thrombocytopenia
Introduction. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. Splenectomy is one the most effective treatment methods for this disorder.Aim — to evaluate the effi cacy and safety of a splenectomy in patients with primary immune thrombocytopenia.Subjects and methods. 111 patients (31 males, 80 females) with primary immune thrombocytopenia who were hospitalized to perform laparoscopic splenectomy were included in a prospective study conducted at the National Research Center for Hematology from 2015 to 2019. Disease duration from onset to splenectomy was from 1 month to 51 years. Response to the splenectomy, complications, and correlation with immediate preoperative platelet count were analyzed.Results. Complete response was achieved in 79 (71.2 %) cases, a partial response was achieved in 11 (9.9 %) cases, and in 21 (18.9 %) cases there was no response. Immediate preoperative platelet count was signifi cantly higher in patients with complete response in comparison with the group with no response, median (95% CI): 47 (35–58) vs 16 (9–20), p < 0.001.Multivariate analysis (logistic regression) was performed. According to this regression, a risk factor for an unfavorable response was detected — males > 60 years of age, p = 0.05; RR (95% CI): 2.0 (0.9–7.1). A predictor of unfavorable response was identifi ed – immediate preoperative platelet count < 23 × 109/l (cutoff point determined in ROC-analysis); p = 0.001, RR (95% CI): 2.5 (1.1–8.6). The probability of complete response was lower with the number of treatment lines prior to splenectomy (weak inverse correlation: r S = −0.30; p = 0.01). The frequency of postoperative complications was 12.6 %. According to our follow-up data, a complete response was preserved in 66/79 (83.5 %) of patients, with a follow-up of 2.7 years.Conclusion. Splenectomy is an effective and safe treatment method for ITP. Factors of unfavorable response were identifi ed: males > 60 years of age and immediate preoperative platelet count < 23 × 109/l. It is safe to perform splenectomy regardless of effectiveness of preoperative splenectomy treatment and platelet count.
- 25 October 2021
- Published by National Medical Research Center of Hematology of the Ministry of Health of the Russian Federation in Russian journal of hematology and transfusiology
- Vol. 66 (3) , 362-373-373
Open AccessEffi cacy of splenectomy in primary immune thrombocytopenia
Introduction. Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by isolated thrombocytopenia. Splenectomy is one the most effective treatment methods for this disorder.Aim — to evaluate the effi cacy and safety of a splenectomy in patients with primary immune thrombocytopenia.Subjects and methods. 111 patients (31 males, 80 females) with primary immune thrombocytopenia who were hospitalized to perform laparoscopic splenectomy were included in a prospective study conducted at the National Research Center for Hematology from 2015 to 2019. Disease duration from onset to splenectomy was from 1 month to 51 years. Response to the splenectomy, complications, and correlation with immediate preoperative platelet count were analyzed.Results. Complete response was achieved in 79 (71.2 %) cases, a partial response was achieved in 11 (9.9 %) cases, and in 21 (18.9 %) cases there was no response. Immediate preoperative platelet count was signifi cantly higher in patients with complete response in comparison with the group with no response, median (95% CI): 47 (35–58) vs 16 (9–20), p < 0.001.Multivariate analysis (logistic regression) was performed. According to this regression, a risk factor for an unfavorable response was detected — males > 60 years of age, p = 0.05; RR (95% CI): 2.0 (0.9–7.1). A predictor of unfavorable response was identifi ed – immediate preoperative platelet count < 23 × 109/l (cutoff point determined in ROC-analysis); p = 0.001, RR (95% CI): 2.5 (1.1–8.6). The probability of complete response was lower with the number of treatment lines prior to splenectomy (weak inverse correlation: r S = −0.30; p = 0.01). The frequency of postoperative complications was 12.6 %. According to our follow-up data, a complete response was preserved in 66/79 (83.5 %) of patients, with a follow-up of 2.7 years.Conclusion. Splenectomy is an effective and safe treatment method for ITP. Factors of unfavorable response were identifi ed: males > 60 years of age and immediate preoperative platelet count < 23 × 109/l. It is safe to perform splenectomy regardless of effectiveness of preoperative splenectomy treatment and platelet count.
- Open Access
- 16 December 2020
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 19 (4) , 10-31
PERIANAL INFECTIOUS COMPLICATIONS IN PATIENTS WITH GRANULOCYTOPENIA AND HAEMATOLOGICAL MALIGNANCIES
ОСОБЕННОСТИ ПЕРИАНАЛЬНЫХ ИНФЕКЦИОННЫХ ОСЛОЖНЕНИЙ У БОЛЬНЫХ ГЕМОБЛАСТОЗАМИ И ГРАНУЛОЦИТОПЕНИЕЙ
- 16 December 2020
- Published by Russian Association of Coloproctology in Koloproktologia
- Vol. 19 (4) , 10-31
Open AccessPERIANAL INFECTIOUS COMPLICATIONS IN PATIENTS WITH GRANULOCYTOPENIA AND HAEMATOLOGICAL MALIGNANCIES
ОСОБЕННОСТИ ПЕРИАНАЛЬНЫХ ИНФЕКЦИОННЫХ ОСЛОЖНЕНИЙ У БОЛЬНЫХ ГЕМОБЛАСТОЗАМИ И ГРАНУЛОЦИТОПЕНИЕЙ
- Open Access
- 15 November 2013
- Published by American Society of Hematology in Blood
- Vol. 122 (21) , 4083
The Role Of Splenectomy In The Treatment Of Myelofibrosis
Splenectomy (SE) at the Myelofibrosis (MF) is one of the difficult operations on the techniques and perioperative complications. There are a lot of complications such as inflammatory and adhesive processes, a massive bleeding associated with disorders of hemostasis in thrombocytopenia or thrombocytosis, enlargement of varicose veins, concomitant pathology. A SE doesn’t cure myelofibrosis but may be performed in some cases. Success is unpredictable, and the operative mortality of SE is on the order of 10%. Evaluate the clinical and hematologic SE efficiency in patients with MF, resistant to traditional treatment. We analyzed the medical case history of 52 patients with MF, which were observed in the National Research Center for Hematology from 2004 to 2013. All patients were performed SE. 47 patients diagnosed with primary MF, and 4 – post-polycitaemic MF and 1 patient post-trombocitaemic MF. PMF was diagnosed according to the criteria established by WHO (2008), which include bone marrow fibrosis, and splenomegaly leyko-eritroblastosis in peripheral blood. The average age at diagnosis was 47 years (24 – 78 years), and before the SE – 53 (25 – 79 years). Women and men ratio was 1.3:1. According to the predictive model of the Dynamic International Prognostic Score System - (DIPSS) 38 (73%) patients before the SE attributed to intermediate risk 2, 14 (27%) patients – high risk. BCR-ABL gene not found a single patient, and the gene mutation JAK2V617F at different stages of the disease is detected in 53% of cases. Genetic adverse factors are not taken into account because of the small number of studies. Massive and huge splenomegaly was present in 37 (71%) patients. Spleen weight 0.9 to 2.9 kg is removed in 15 (29%) patients, from 3 to 7 kg is removed in 35 (67%) patients. In two cases, removal of the spleen weight of 10 and 11 kg. Statistical analysis were done using SAS 9.3 and JMP 10.0 (SAS Institute Inc., Cary, NC). Disease duration was about 76 months and ranged from 1 to 240 months. Surgical complications occurred in 21 patients, including bleeding 3, thrombosis 1, infection 2. Surgical complications from SE in intra-and early postoperative period was 8% from 1978 to 2003. Surgical complications from SE in intra-and early postoperative period was not fixed from 2004 to 2013. After SE complications were hepatomegaly, resistant thrombocytosis (platelet count ≥ 600 × 109/L), leukocytosis (white blood cell count greater than 10 x 109/l) and blast transformation of the disease. More than 80% of patients after SE had no symptoms of intoxication. 22 patients with MF had transfusion dependent anemia, 11 (50%) had disappeared transfusion requirements after SE in and the effect lasted for about a year. Only 4 of the 15 patients with thrombocytopenia who underwent SE due to refractory thrombocytopenia were observed a significant increase in platelet count above 100h109 / L, for an average of 6 months. The possibility of the resumption of long-term cytoreductive therapy appeared in 30 (58%) patients. Currently alive 19 (37%) patients, mean follow-up was 37 months (4 to 72 months) after the SE and of 105 (12-264) months after diagnosis. 33 (63%) patients died during the observation period after SE (1 – 84 months, mean – 27 months). Among these, 27 (82%) patients died of transformation disease and 6 (18%) died of comorbidity. 19 (37%) patients, with a mean follow-up of 37 months after SE (from 4 to 72 months) continue treatment with hydroxyurea. Median survival after SE is 3 years (Figure 1), with a median overall survival - 11 years (Figure 2). Figure 1. Figure 1. Figure 2. Figure 2. Despite the potential complications SE is an effective palliative method for patients with MF in the absence of leukemic progression. SE indicated in patients with drug refractory MF, acute constitutional symptoms, anemia, transfusion-dependent, and portal hypertension. Modern methods of surgery, as well as supporting therapy in the perioperative period can safely perform the SE. No relevant conflicts of interest to declare.
- 15 November 2013
- Published by American Society of Hematology in Blood
- Vol. 122 (21) , 4083
Open AccessThe Role Of Splenectomy In The Treatment Of Myelofibrosis
Splenectomy (SE) at the Myelofibrosis (MF) is one of the difficult operations on the techniques and perioperative complications. There are a lot of complications such as inflammatory and adhesive processes, a massive bleeding associated with disorders of hemostasis in thrombocytopenia or thrombocytosis, enlargement of varicose veins, concomitant pathology. A SE doesn’t cure myelofibrosis but may be performed in some cases. Success is unpredictable, and the operative mortality of SE is on the order of 10%. Evaluate the clinical and hematologic SE efficiency in patients with MF, resistant to traditional treatment. We analyzed the medical case history of 52 patients with MF, which were observed in the National Research Center for Hematology from 2004 to 2013. All patients were performed SE. 47 patients diagnosed with primary MF, and 4 – post-polycitaemic MF and 1 patient post-trombocitaemic MF. PMF was diagnosed according to the criteria established by WHO (2008), which include bone marrow fibrosis, and splenomegaly leyko-eritroblastosis in peripheral blood. The average age at diagnosis was 47 years (24 – 78 years), and before the SE – 53 (25 – 79 years). Women and men ratio was 1.3:1. According to the predictive model of the Dynamic International Prognostic Score System - (DIPSS) 38 (73%) patients before the SE attributed to intermediate risk 2, 14 (27%) patients – high risk. BCR-ABL gene not found a single patient, and the gene mutation JAK2V617F at different stages of the disease is detected in 53% of cases. Genetic adverse factors are not taken into account because of the small number of studies. Massive and huge splenomegaly was present in 37 (71%) patients. Spleen weight 0.9 to 2.9 kg is removed in 15 (29%) patients, from 3 to 7 kg is removed in 35 (67%) patients. In two cases, removal of the spleen weight of 10 and 11 kg. Statistical analysis were done using SAS 9.3 and JMP 10.0 (SAS Institute Inc., Cary, NC). Disease duration was about 76 months and ranged from 1 to 240 months. Surgical complications occurred in 21 patients, including bleeding 3, thrombosis 1, infection 2. Surgical complications from SE in intra-and early postoperative period was 8% from 1978 to 2003. Surgical complications from SE in intra-and early postoperative period was not fixed from 2004 to 2013. After SE complications were hepatomegaly, resistant thrombocytosis (platelet count ≥ 600 × 109/L), leukocytosis (white blood cell count greater than 10 x 109/l) and blast transformation of the disease. More than 80% of patients after SE had no symptoms of intoxication. 22 patients with MF had transfusion dependent anemia, 11 (50%) had disappeared transfusion requirements after SE in and the effect lasted for about a year. Only 4 of the 15 patients with thrombocytopenia who underwent SE due to refractory thrombocytopenia were observed a significant increase in platelet count above 100h109 / L, for an average of 6 months. The possibility of the resumption of long-term cytoreductive therapy appeared in 30 (58%) patients. Currently alive 19 (37%) patients, mean follow-up was 37 months (4 to 72 months) after the SE and of 105 (12-264) months after diagnosis. 33 (63%) patients died during the observation period after SE (1 – 84 months, mean – 27 months). Among these, 27 (82%) patients died of transformation disease and 6 (18%) died of comorbidity. 19 (37%) patients, with a mean follow-up of 37 months after SE (from 4 to 72 months) continue treatment with hydroxyurea. Median survival after SE is 3 years (Figure 1), with a median overall survival - 11 years (Figure 2). Figure 1. Figure 1. Figure 2. Figure 2. Despite the potential complications SE is an effective palliative method for patients with MF in the absence of leukemic progression. SE indicated in patients with drug refractory MF, acute constitutional symptoms, anemia, transfusion-dependent, and portal hypertension. Modern methods of surgery, as well as supporting therapy in the perioperative period can safely perform the SE. No relevant conflicts of interest to declare.